ABL Diagnostics (XPAR:ABLD) EBITDA: €1.01 Mil (TTM As of Dec. 2025)


XPAR:ABLD ABL Diagnostics XPAR:ABLD
51 GF Score
Price €2.66
GF Value €7.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics EBITDA?

ABL Diagnostics XPAR:ABLD +0.76% 51 EBITDA is €1.01 Mil as of Dec. 2025. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ABL Diagnostics's EBITDA for the six months ended in Dec. 2025 was €0.65 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.01 Mil.

During the past 12 months, the average EBITDA Growth Rate of ABL Diagnostics was 203.30% per year. During the past 3 years, the average EBITDA Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of ABL Diagnostics was 49.80% per year. The lowest was -40.40% per year. And the median was 7.45% per year.

ABL Diagnostics's EBITDA per Share for the six months ended in Dec. 2025 was €0.04. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.

During the past 12 months, the average EBITDA per Share Growth Rate of ABL Diagnostics was 200.00% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of ABL Diagnostics was 49.60% per year. The lowest was -44.20% per year. And the median was 7.80% per year.

ABL Diagnostics  (XPAR:ABLD) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


ABL Diagnostics EBITDA Related Terms


ABL Diagnostics EBITDA Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics EBITDA Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 0.65 0.05 0.33 1.01

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.12 0.22 0.37 0.65

XPAR:ABLD vs VEEV, BTSG, TEM: EBITDA Comparison

For the Health Information Services subindustry, ABL Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics EV-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's EV-to-EBITDA falls into.


XPAR:ABLD
51GF Score
ABL Diagnostics XPAR:ABLD
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

ABL Diagnostics's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

ABL Diagnostics's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, ABL Diagnostics's EBITDA was €1.01 Mil.

ABL Diagnostics's EBITDA for the quarter that ended in Dec. 2025 is calculated as

ABL Diagnostics's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, ABL Diagnostics's EBITDA was €0.65 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of €1.01 Mil mean?
ABL Diagnostics (XPAR:ABLD) has a EBITDA of €1.01 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on ABL Diagnostics.
Is ABL Diagnostics' EBITDA too high?
ABL Diagnostics' current EBITDA is €1.01 Mil. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EBITDA compare to VEEV and BTSG?
ABL Diagnostics' EBITDA of €1.01 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Healthcare Providers & Services company?
A good EBITDA depends on the Healthcare Providers & Services industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on ABL Diagnostics. ABL Diagnostics's current EBITDA is €1.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current EBITDA is €1.01 Mil. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current EBITDA is €1.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • EBITDA: €1.01 Mil
  • GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score

Get the complete analysis for XPAR:ABLD

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€7.71
GF Value